Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design

NCT07398417 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

620

Enrollment

INDUSTRY

Sponsor class

Conditions

Fibromyalgia

Interventions

DRUG: AXS-14 (Esreboxetine)
DRUG: Placebo

Sponsor

Axsome Therapeutics, Inc.